In vitro and in vivo effects of tetrakisphosphonates on bone resorption, tumor osteolysis, ectopic calcification, and macrophages
- PMID: 9050794
- DOI: 10.1021/js960429h
In vitro and in vivo effects of tetrakisphosphonates on bone resorption, tumor osteolysis, ectopic calcification, and macrophages
Abstract
The biological effects of bisphosphonates in calcium-related disorders are attributed to the incorporation of the bisphosphonates in bone, enabling direct interaction with osteoclasts and/or osteoblasts. The high accumulation of bisphosphonates in bone, due to their high affinity to hydroxyapatite (HAP), is essential for mediating in vitro and in vivo activity. In this study we examined the activity of tetrakisphosphonates, molecules containing two P-C-P type bisphosphonate moieties connected by a carbon chain. The novel compounds were examined in a battery of in vitro and in vivo models including HAP formation and dissolution, ectopic calcification, bone resorption, tumor osteolysis, and of macrophage-like cells (anti- or pro-inflammatory properties). The inhibition of ectopic calcification was ranked as follows: geminal bisphosphonates > bisacylphosphonates > tetrakisphosphonates. Pamidronate, but not the tetrakisphosphonates, was an effective antiosteolytic agent. Neither DNTP (tetrasodium 1,9-dihydroxynonane 1,1,9,9-tetrakisphosphonate) nor the bisacylphosphonate, PiBP (pimeloylbisphosphonate) seem to possess strong macrophage suppressive or inductive effects and can be considered to be relatively inactive in terms of anti- or pro-inflammatory action. A significant anticalcification effect was caused by various phosphonates, such as the tetrakisphosphonates, but DNTP, a tetrakisphosphonate, was found toxic as it impeded somatic growth and bone development.
Similar articles
-
Growth inhibition of macrophage-like and other cell types by liposome-encapsulated, calcium-bound, and free bisphosphonates in vitro.J Drug Target. 1994;2(4):299-308. doi: 10.3109/10611869409015910. J Drug Target. 1994. PMID: 7858955
-
Mechanisms of action of the bisphosphonates.Medicina (B Aires). 1997;57 Suppl 1:65-75. Medicina (B Aires). 1997. PMID: 9567358
-
In vitro and in vivo anticalcification effects of novel bishydroxyiminophosphonates.J Pharm Sci. 1992 Oct;81(10):1004-7. doi: 10.1002/jps.2600811009. J Pharm Sci. 1992. PMID: 1432609
-
Bisphosphonates: a new class of drugs in diseases of bone and calcium metabolism.Recent Results Cancer Res. 1989;116:1-28. doi: 10.1007/978-3-642-83668-8_1. Recent Results Cancer Res. 1989. PMID: 2669065 Review.
-
Bisphosphonates: the first 40 years.Bone. 2011 Jul;49(1):2-19. doi: 10.1016/j.bone.2011.04.022. Epub 2011 May 1. Bone. 2011. PMID: 21555003 Review.
Cited by
-
The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis.Curr Rheumatol Rep. 2014 Dec;16(12):467. doi: 10.1007/s11926-014-0467-y. Curr Rheumatol Rep. 2014. PMID: 25366934 Free PMC article. Review.
-
Immobilized Bisphosphonates as Potential Inhibitors of Bioprosthetic Calcification: Effects on Various Xenogeneic Cardiovascular Tissues.Biomedicines. 2021 Dec 29;10(1):65. doi: 10.3390/biomedicines10010065. Biomedicines. 2021. PMID: 35052745 Free PMC article.
-
Phosphonic Acid Coupling Agent Modification of HAP Nanoparticles: Interfacial Effects in PLLA/HAP Bone Scaffold.Polymers (Basel). 2020 Jan 13;12(1):199. doi: 10.3390/polym12010199. Polymers (Basel). 2020. PMID: 31940986 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources